Both medications can cause mild gastrointestinal side effects
At 20 weeks, mean weight loss was 10.6% of body weight but, at 68 weeks, those who were switched to placebo regained 6.9% of their 20-week weight
GLP-1 receptor activation can reduce neuroinflammation and oxidative stress, and restore insulin signaling, which may compensate for the dysfunctional dopaminergic neurotransmission and motor deficits associated with PD pathogenesis [74, 75]
Appetite and Satiety : By activating GLP-1 and GIP receptors, Zepbound slows down digestion, reduces appetite, and prolongs the feeling of fullness, helping users to eat less over time
Prescription medications like Semaglutide and Tirzepatide require a consultation and assessment through TrimRx to ensure safety and efficacy